Premium
Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems
Author(s) -
Narmani Asghar,
Rezvani Melina,
Farhood Bagher,
Darkhor Parvaneh,
Mohammadnejad Javad,
Amini Bahram,
Refahi Soheila,
Abdi Goushbolagh Nouraddin
Publication year - 2019
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.21545
Subject(s) - drug delivery , biodistribution , pharmacology , bioavailability , targeted drug delivery , drug , pharmacokinetics , chemistry , in vivo , cancer therapy , chemotherapy , folate receptor , cancer , medicine , cancer cell , nanotechnology , in vitro , materials science , biochemistry , biology , microbiology and biotechnology
Conventional chemotherapeutic approaches in cancer therapy such as surgery, chemotherapy, and radiotherapy have several disadvantages due to their nontargeted distributions in the whole body. On the other hand, nanoparticles (NPs) based therapies are remarkably progressing to solve several limitations of conventional drug delivery systems (DDSs) including nonspecific biodistribution and targeting, poor water solubility, weak bioavailability and biodegradability, low pharmacokinetic properties, and so forth. The enhanced permeability and retention effect escape from P‐glycoprotein trap in cancer cells as a passive targeting mechanism, and active targeting strategies are also other most important advantages of NPs in cancer diagnosis and therapy. Folic acid (FA) is one of the biologic molecules which has been targeted overexpressed‐folic acid receptor (FR) on the surface of cancer cells. Therefore, conjugation of FA to NPs most easily enhances the FR‐mediated targeting delivery of therapeutic agents. Here, the recent works in FA which have been decorated NPs‐based DDSs are discussed and cancer therapy potency of these NPs in clinical trials are presented.